The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.

AusPAR: Pazopanib hydrochloride

Australian Public Assessment Report

AusPAR

AusPAR: Pazopanib hydrochloride [PDF, 687.46 KB]

AusPAR: Pazopanib hydrochloride [Word, 1.14 MB]

Attachment: Product Information: Pazopanib hydrochloride [PDF, 348.14 KB]

Attachment: Product Information: Pazopanib hydrochloride [Word, 296.18 KB]

Attachment: Extract from Clinical Evaluation Report: Pazopanib hydrochloride [PDF, 628.19 KB]

Attachment: Extract from Clinical Evaluation Report: Pazopanib hydrochloride [Word, 1.04 MB]

Device/Product Name

Votrient

Active ingredients

Pazopanib hydrochloride

AusPAR Date

25 February 2013

Published

19 July 2013

Submission Number

PM-2011-01972-3-4

Submission Type

Extension of indications

Decision

Approved